Clinical Trial Update: Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT [Phase 4]

View source ↗

Summary

Phase 4 trial exploring secondary prophylaxis of CMV reactivation with letermovir after HID-HSCT; efficacy and safety being evaluated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients

Drugs mentioned

• let ermovir (letermovir)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation | Phase 4 | Status: UNKNOWN